LT2837680T - Žinduolių ląstelių kultūra - Google Patents

Žinduolių ląstelių kultūra

Info

Publication number
LT2837680T
LT2837680T LTEP14187232.5T LT14187232T LT2837680T LT 2837680 T LT2837680 T LT 2837680T LT 14187232 T LT14187232 T LT 14187232T LT 2837680 T LT2837680 T LT 2837680T
Authority
LT
Lithuania
Prior art keywords
cell culture
mammalian cell
mammalian
culture
cell
Prior art date
Application number
LTEP14187232.5T
Other languages
English (en)
Inventor
Brian FOLLSTAD
Rebecca Mccoy
Arvia Morris
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46579326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2837680(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of LT2837680T publication Critical patent/LT2837680T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
LTEP14187232.5T 2011-07-01 2012-06-29 Žinduolių ląstelių kultūra LT2837680T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161503737P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
LT2837680T true LT2837680T (lt) 2020-07-10

Family

ID=46579326

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP14187232.5T LT2837680T (lt) 2011-07-01 2012-06-29 Žinduolių ląstelių kultūra
LTEP12738674.6T LT2726600T (lt) 2011-07-01 2012-06-29 Žinduolių ląstelių kultūra

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP12738674.6T LT2726600T (lt) 2011-07-01 2012-06-29 Žinduolių ląstelių kultūra

Country Status (24)

Country Link
US (7) US11292829B2 (lt)
EP (2) EP2726600B1 (lt)
JP (1) JP5897708B2 (lt)
KR (7) KR20240005106A (lt)
CN (2) CN103827292B (lt)
AU (5) AU2012279230B2 (lt)
BR (2) BR122021007265B1 (lt)
CA (2) CA2838695C (lt)
CL (2) CL2013003792A1 (lt)
CY (2) CY1118863T1 (lt)
DK (2) DK2837680T3 (lt)
EA (1) EA039023B1 (lt)
ES (2) ES2625045T3 (lt)
HK (2) HK1206057A1 (lt)
HU (2) HUE049119T2 (lt)
IL (5) IL288509B2 (lt)
LT (2) LT2837680T (lt)
MX (1) MX351974B (lt)
PL (2) PL2726600T3 (lt)
PT (2) PT2837680T (lt)
SG (1) SG10201702537RA (lt)
SI (2) SI2837680T1 (lt)
WO (1) WO2013006479A2 (lt)
ZA (1) ZA201309372B (lt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2008033517A2 (en) 2006-09-13 2008-03-20 Abbott Laboratories Cell culture improvements
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
LT2837680T (lt) * 2011-07-01 2020-07-10 Amgen Inc. Žinduolių ląstelių kultūra
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
HUE045624T2 (hu) 2011-10-18 2020-01-28 Coherus Biosciences Inc Magnézium ionokkal stabilizált etanercept készítmények
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
PE20150762A1 (es) 2012-07-09 2015-06-20 Coherus Biosciences Inc Formulaciones de etanercept que muestran una marcada reduccion de la cantidad de particulas subvisibles
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
JP2015533797A (ja) 2012-09-11 2015-11-26 コヒラス・バイオサイエンシズ・インコーポレイテッド 高純度および優れた収率の正確に折り畳まれたエタネルセプト
US20140199728A1 (en) * 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
TWI771890B (zh) * 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
MX362922B (es) * 2013-03-26 2019-02-25 Coherus Biosciences Inc Método de producción de proteínas.
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US11130980B2 (en) * 2013-10-31 2021-09-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
CN112481337A (zh) 2014-01-13 2021-03-12 美国安进公司 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
MX362923B (es) 2014-01-30 2019-02-25 Coherus Biosciences Inc Medios de perfusión.
ES2709994T3 (es) 2014-06-04 2019-04-22 Amgen Inc Métodos de recolección en cultivos de células de mamífero
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
TWI776235B (zh) * 2014-06-09 2022-09-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
JP6530171B2 (ja) * 2014-09-09 2019-06-12 旭化成メディカル株式会社 培養産生物の回収方法
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
KR102007930B1 (ko) * 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105385731B (zh) * 2015-12-25 2018-10-30 上海莱士血液制品股份有限公司 一种表达重组八因子的灌注培养方法
EP3400242A1 (en) * 2016-01-06 2018-11-14 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
US11377677B2 (en) 2016-03-02 2022-07-05 Lonza Ltd Fermentation process
WO2018178069A1 (en) * 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Perfusion medium
EP3601584A1 (en) * 2017-03-31 2020-02-05 Boehringer Ingelheim International GmbH Perfusion medium
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
US11609120B2 (en) 2017-10-06 2023-03-21 Lonza Ltd Automated control of cell culture using Raman spectroscopy
CA3075679A1 (en) 2017-10-16 2019-04-25 Regeneron Pharmaceuticals, Inc. Perfusion bioreactor and related methods of use
CA3084445A1 (en) * 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
CA3122774A1 (en) 2018-12-31 2020-07-09 Repligen Corporation Filter for mammalian cell culture perfusion and clarification with hydrophobic hollow fiber
KR20230042125A (ko) * 2020-08-14 2023-03-27 브리스톨-마이어스 스큅 컴퍼니 단백질에 대한 제조 공정
BR112023003273A2 (pt) * 2020-08-31 2023-05-02 Regeneron Pharma Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
WO2022066595A1 (en) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
CN114574430A (zh) * 2022-03-22 2022-06-03 成都博宠生物科技有限公司 一种Expi293F细胞培养方法
CN115287251A (zh) * 2022-08-25 2022-11-04 无锡药明生物技术股份有限公司 间歇性灌流联合分批流加培养
WO2024054414A1 (en) 2022-09-06 2024-03-14 Amgen Inc. Lean perfusion cell culture methods
WO2024059235A2 (en) 2022-09-16 2024-03-21 Amgen Inc. A method for harvesting products from perfusion cultures
CN116790483B (zh) * 2023-08-22 2023-10-20 苏州依科赛生物科技股份有限公司 一种cho细胞无血清培养基及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4499064A (en) 1982-06-03 1985-02-12 Clayton Foundation For Research Assessment of nutritional status of individuals
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
US5045468A (en) * 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5143842A (en) * 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0417563T3 (da) 1989-09-12 2000-11-06 Hoffmann La Roche TNF-bindende proteiner
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
US7037721B1 (en) * 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DK0835305T3 (da) 1995-06-29 2006-02-13 Immunex Corp Cytokin som inducerer apoptose
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
JP2000517188A (ja) 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
US20030036505A1 (en) 2000-09-25 2003-02-20 Human Genome Sciences, Inc. Signal transduction pathway component polynucleotides, polypeptides, antibodies and methods based thereon
US20030087372A1 (en) 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AU2003220529B2 (en) 2002-03-27 2006-09-07 Immunex Corporation Methods for increasing polypeptide production
CN1930281A (zh) * 2004-03-05 2007-03-14 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
CN1332024C (zh) * 2004-06-09 2007-08-15 中国科学院大连化学物理研究所 一种海绵细胞的微载体三维培养方法
ATE505219T1 (de) 2004-07-07 2011-04-15 Coloplast As Katheter enthaltend estane 58212
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
EP1812557A4 (en) * 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
ATE557038T1 (de) 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
US8119368B2 (en) 2006-07-14 2012-02-21 Dsm Ip Assets B.V. Process for the culturing of cells
US20080206819A1 (en) * 2006-08-21 2008-08-28 Mary Tsao Intensified Perfusion Production Method
PL2078071T3 (pl) 2006-11-08 2015-07-31 Wyeth Llc Racjonalnie opracowane pożywki do hodowli komórek
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
ES2657055T3 (es) 2007-08-09 2018-03-01 Wyeth Llc Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores
WO2010031074A2 (en) 2008-09-15 2010-03-18 Genentech, Inc. Compositions and methods for regulating cell osmolarity
CN101603026B (zh) * 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
KR101756354B1 (ko) 2009-07-31 2017-07-26 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
PT2464725T (pt) 2009-08-11 2020-05-21 Hoffmann La Roche Produção de proteínas em meios de cultura celular isentos de glutamina
US8765415B2 (en) 2009-11-17 2014-07-01 Medarex, L.L.C. Methods for enhanced protein production
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
CA2816520C (en) * 2010-11-01 2017-11-21 Symphogen A/S Anti-her3 antibodies and compositions
WO2012145682A1 (en) * 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
LT2837680T (lt) * 2011-07-01 2020-07-10 Amgen Inc. Žinduolių ląstelių kultūra
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US11130980B2 (en) 2013-10-31 2021-09-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
KR102069988B1 (ko) * 2015-11-17 2020-01-23 화이자 인코포레이티드 박테리아 세포 배양에서 폴리사카라이드를 생성하기 위한 배지 및 발효 방법

Also Published As

Publication number Publication date
US11827692B2 (en) 2023-11-28
EA039023B1 (ru) 2021-11-23
AU2018203972B2 (en) 2020-09-17
PL2837680T3 (pl) 2020-08-10
SG10201702537RA (en) 2017-04-27
KR101662412B1 (ko) 2016-10-04
AU2016244255A1 (en) 2016-10-27
CL2016001190A1 (es) 2017-06-09
ES2788132T3 (es) 2020-10-20
PL2726600T3 (pl) 2017-08-31
SI2726600T1 (sl) 2017-07-31
IL310968A (en) 2024-04-01
US11673941B2 (en) 2023-06-13
CA2838695A1 (en) 2013-01-10
WO2013006479A3 (en) 2013-03-28
KR102108663B1 (ko) 2020-05-07
KR20240005106A (ko) 2024-01-11
CN107988166B (zh) 2022-03-15
BR112013033730B1 (pt) 2022-01-25
EP2726600A2 (en) 2014-05-07
KR102358951B1 (ko) 2022-02-08
AU2020281075B2 (en) 2022-12-22
KR20220021008A (ko) 2022-02-21
US11292829B2 (en) 2022-04-05
KR101857380B1 (ko) 2018-05-11
BR112013033730A2 (pt) 2017-01-31
US20140255993A1 (en) 2014-09-11
ES2625045T3 (es) 2017-07-18
EP2837680B1 (en) 2020-02-26
HUE049119T2 (hu) 2020-09-28
BR122021007265B1 (pt) 2022-02-22
AU2023201127A1 (en) 2023-03-30
PT2837680T (pt) 2020-04-17
AU2012279230A1 (en) 2014-01-09
KR20140031375A (ko) 2014-03-12
SI2837680T1 (sl) 2020-07-31
US20230227535A1 (en) 2023-07-20
DK2837680T3 (da) 2020-04-27
IL297998B1 (en) 2024-03-01
LT2726600T (lt) 2017-05-25
EP2726600B1 (en) 2017-02-15
EA201391826A1 (ru) 2014-04-30
CN103827292B (zh) 2018-01-26
CA2952347A1 (en) 2013-01-10
AU2018203972A1 (en) 2018-06-21
KR20230114317A (ko) 2023-08-01
JP2014520534A (ja) 2014-08-25
MX351974B (es) 2017-11-06
US20200407427A1 (en) 2020-12-31
KR20160075814A (ko) 2016-06-29
AU2012279230B2 (en) 2016-08-18
HK1197081A1 (en) 2015-01-02
ZA201309372B (en) 2014-08-27
IL278430B (en) 2022-01-01
CA2838695C (en) 2017-02-14
US11634476B2 (en) 2023-04-25
KR20180050433A (ko) 2018-05-14
CY1118863T1 (el) 2018-01-10
IL288509A (en) 2022-01-01
EP2837680A1 (en) 2015-02-18
CY1123146T1 (el) 2021-12-31
JP5897708B2 (ja) 2016-03-30
US20230117598A1 (en) 2023-04-20
KR20200051046A (ko) 2020-05-12
US11685772B2 (en) 2023-06-27
CN107988166A (zh) 2018-05-04
CL2013003792A1 (es) 2014-07-25
KR102558247B1 (ko) 2023-07-24
HK1206057A1 (en) 2015-12-31
CN103827292A (zh) 2014-05-28
IL288509B (en) 2022-12-01
HUE033279T2 (en) 2017-11-28
US20210061888A1 (en) 2021-03-04
AU2020281075A1 (en) 2021-01-07
PT2726600T (pt) 2017-04-24
WO2013006479A2 (en) 2013-01-10
US20220185869A1 (en) 2022-06-16
IL297998A (en) 2023-01-01
US20230129523A1 (en) 2023-04-27
IL288509B2 (en) 2023-04-01
DK2726600T3 (en) 2017-05-15
MX2013014937A (es) 2014-04-16
IL229803B (en) 2020-11-30

Similar Documents

Publication Publication Date Title
IL288509A (en) Mammalian cell culture
SG10201601434RA (en) Cell Culture System
EP2729561A4 (en) CELL CULTURE METHOD
EP2759592A4 (en) ADHÄSIONSZELLKULTURVERFAHREN
HK1183057A1 (en) Cell culture insert
IL226971B (en) Cell culture medium
SG11201503579RA (en) Cell culture med
EP2772530A4 (en) CELL CULTURE ASSAY
EP3144319B8 (en) Cell culture composition comprising laminin-521
SG10201700670WA (en) Cell culture
EP2796537A4 (en) CELL CULTURE SUPPORT
HUE058968T2 (hu) Sejtkultúra tenyésztésére szolgáló eszköz
GB201211873D0 (en) Cell culture
GB201114752D0 (en) Cell staining process
GB201007863D0 (en) Bioreactor for cell culture
GB201120446D0 (en) Mammalian cell transformation method
GB201007855D0 (en) Bioreactor for the culture of cells
GB201016327D0 (en) Mammalian cell preservation methods
AU2011903899A0 (en) Cell culture & expansion
GB201000999D0 (en) Mammalian cell preservation methods
PL393251A1 (pl) Mikroukład do hodowli komórkowej
GB201115343D0 (en) Mammalian Haploid embryonic stem cells
GB201110577D0 (en) Culturing microorganisms
GB201020075D0 (en) Mammalian cell transformation method